Glioblastoma

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
Thursday, March 7, 2024

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 5, 2024

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.
  • Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated dose, and recommended Phase 2 dose.
  • Implement Plus’ CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay as an exploratory clinical endpoint in all ReSPECT-LM trial patients in Q1 2024.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024

BASKING RIDGE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.

Key Points: 
  • Conference call scheduled for today at 4:30 p.m. Eastern time
    BASKING RIDGE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.
  • Lisata and its development collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics.
  • As of December 31, 2023, Lisata had cash, cash equivalents, and marketable securities of approximately $50.5 million.
  • Lisata will hold a live conference call on Thursday, February 29, 2024 at 4:30 p.m. Eastern time to discuss financial results, provide a business update and answer questions.

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Retrieved on: 
Thursday, March 7, 2024

One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.

Key Points: 
  • One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.
  • Twenty-nine of the 58 patients with recurrent high-grade glioma brain tumors, mostly glioblastoma, achieved stable disease after treatment with CAR T cells for at least two months.
  • There were two partial responses, one complete response and a second complete response after additional CAR T cell therapy cycles were delivered under compassionate use.
  • The study team also included researchers from Translational Genomics Research Institute in Phoenix, which is part of City of Hope.

Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024

The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.
  • Beyond monotherapies, combination strategies are also being explored in preclinical and clinical trials to enhance PRMT5 inhibition efficacy.
  • However, realizing the full clinical and commercial potential will require validating efficacy and defining suitable patient populations through biomarker-guided trials.
  • Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 Report Highlights:
    PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
    PRMT5 Targeted Therapies in Clinical Trials: >25
    PRMT5 Targeted Therapies Research & Market Trends by Region: US, UK, EU, China & Canada

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, February 22, 2024

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.
  • “In 2023, we reached many milestones in our commercial, clinical and product development programs,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • Operational updates for the fourth quarter ended December 31, 2023:
    1,564 prescriptions were received in the quarter, an increase of 14% year-over-year.
  • Novocure will host a conference call and webcast to discuss fourth quarter and full year 2023 financial results at 8:00 a.m. EST today, Thursday, February 22, 2024.

Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham

Retrieved on: 
Wednesday, February 21, 2024

ft. of lab and office space at 300 Third Avenue in Waltham, Mass.

Key Points: 
  • ft. of lab and office space at 300 Third Avenue in Waltham, Mass.
  • View the full release here: https://www.businesswire.com/news/home/20240221278304/en/
    300 Third Avenue in Waltham, Massachusetts.
  • 300 Third Avenue is a 143,533-sq.-ft. purpose-built life science building with four stories of laboratory space and 441 on-site parking spaces.
  • Lincoln Property Company (“Lincoln”) is one of the largest diversified real estate services companies with 35 offices across the United States the United Kingdom and Europe.

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.

Key Points: 
  • The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
  • In this humanized mouse model, researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC.
  • "Today's bolus of compelling data validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments.
  • We look forward to continuing to evaluate the ONCOPREX Delivery System using both REQORSA and NPRL2 as potential treatments for lung cancer."

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Retrieved on: 
Thursday, February 22, 2024

WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.

Key Points: 
  • WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
  • During the conference, Dr. Marcus will conduct one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
  • Cantex is developing azeliragon, an oral inhibitor of the receptor for advanced glycation end products (known as RAGE).
  • Cantex has ongoing Phase 2 clinical trials in top US and EU medical centers in glioblastoma, brain metastasis, metastatic pancreatic cancer, and breast cancer, and a Phase 3 randomized, placebo-controlled clinical trial in hospitalized patients with pneumonia.